Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 12c, Revenues Beat

Go back to Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 12c, Revenues Beat

Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

March 4, 2021 7:30 AM EST

Initiated Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients

On Track to Initiate Two Additional Clinical Trials Across Hematology Franchise in 2H 2021

On Track to Report Additional Dose-Escalation Data for SY-5609 in Select Solid Tumors in Q3 2021, with Expansion Phase of Trial Expected to Begin in 2H 2021

Well-funded with Cash Runway into 2023, Through Multiple Potential Value Drivers

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE,... More